Skip to content
OpenCapital
Get started

Ligand Pharmaceuticals LGND Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%—
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0×0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Ligand Pharmaceuticals's debt securities, held-to-maturity, amortized cost, after allowance for credit loss, maturity, allocated and single maturity date?
Ligand Pharmaceuticals (LGND) reported debt securities, held-to-maturity, amortized cost, after allowance for credit loss, maturity, allocated and single maturity date of $588.75M in Q1 2026.
How has Ligand Pharmaceuticals's debt securities, held-to-maturity, amortized cost, after allowance for credit loss, maturity, allocated and single maturity date changed year-over-year?
Ligand Pharmaceuticals's debt securities, held-to-maturity, amortized cost, after allowance for credit loss, maturity, allocated and single maturity date increased by 354.1% year-over-year, from $129.65M to $588.75M.